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Recent evidence suggests that CTL recognize the peptide degradation products
of viral proteins presented at the surface of infected cells in association with class
I molecules of the MHC (1-12). However, the mechanisms by which peptide epi-
topes are generated and transported to the cell surface in vivo are not known .
There aretwomodels that couldexplainthemechanism ofpresentation ofa viral
peptide epitope at the cell surface. Viral proteins may be degraded by proteases in
the cytoplasm to form short peptide epitopes . These peptides would then have to
contain all the necessary information to cross abilipid membrane in order to reach
the cell surface (1, 2) . Alternatively, larger protein fragments may be transported
across a bilipid membrane before degradation, in which case signals for transport
could be encoded separately to those forming the minimal epitope .
In previous work (1, 13)we have shown that presentation of epitopes does not de-
pend on a single identifiable signal sequence in either the influenza nucleoprotein
(NP) or haemagglutinin (HA) . However, these experiments involved expression of
protein fragments >130 amino acids long, and could not rule out a role for amino
acid sequences outside the minimal epitopes defined with synthetic peptides . A re-
cent report (14) describes recognition by CTLof cells that synthesize ahydrophobic
fragment of 41 amino acids derived from the transmembrane region of influenza
HA . However, this fragment is also longer than the minimal epitopecontained within
it (6) .
To try and resolve this issue, we have constructed a recombinant vaccinia virus
designed to express a minimal peptide epitope consisting of 15 amino acids of the
influenza NP in the cytoplasm of infected cells . We report here that target cells in-
fected with this recombinant vaccinia virus are recognized efficiently by class I-re-
stricted CTL, suggesting that transport of the epitope to the cell surface requires
no additional sequence information. This observation is consistent with the first sug-
gested model and implies that a peptide transport system exists in eukaryotic cells .
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Materials and Methods
Construction of366-379-NP-VAC 75K.
￿
Two oligonucleotides 66 bases long were synthe-
sized on a DNA synthesizer (381A; Applied Biosystems, Inc., Foster City, CA). They were
designed so that when annealed they would consist ofasequence that would ligate to a Hind
III site, the initiator methionine codon together with the preceding nine nucleotides of un-
translated sequence of the influenza A/NT/60/68 NP gene (15), and the codons for amino
acids 366-379 of NP, followed by two stop codons and a sequence that would ligate to Bam
HI site. The sequences ofthe oligonucleotides were: (5')-AGCTTATCAAAATCATGGCTT
CAAATGAAAACATGGATGCTATGGAATCAAGTACTCTTTGATAAG-(3') and (5')-GAT
CCTTATCAAAGAGTACTTGATTCCATAGCATCCATGTTTTCATTTGAAGCCATG-
ATTTTGATA-(3'). They encode the amino acid sequence met-ala-ser-asn-glu-asn-met-asp-
ala-met-glu-ser-ser-thr-leu. Thegel-purified oligonucleotides were annealed andligatedinto
Hind III and Bam HI cut pKG18 downstream of the 7.5-kD vaccinia promoter, which is
active during both early and late phases of infection (16). pKG18 was derived from pGS62
(16) and contains extra cloning sites for expression (K. Gould; unpublished results). After
the ligation, the construct was checked by DNA sequencing.
Production of recombinantvaccinia virus by insertion into the tk gene followed standard
procedures (16). Recombinants were identified by hybridization with one of the 12P-labeled
oligonucleotides describedabove, and plaque purified twice. The vaccinia expressing residues
366-379 from influenza A/NT/60/68 NP will be referred to as 366-379-NP-VAC 7.5K.
A control vaccinia expressing a rapidly degraded form of the full-length influenza
A/NT/60/68 NP fused to murine ubiquitin (Ub-Arg-NP-VAC 7.5K) hasbeen described(17).
We have previously shown that L/Db cells infected with this virus are recognized by class
I-restricted CTL from CBA (H2-k) andC57BL(H2-b) mice as efficiently as influenza-infected
cells (17).
CTL Cultures, Clones, andRptides.
￿
Clone F5 is specific for the sequence 366-379 derived
from the NP of influenza A/NT/60/68 in association with H-2Db and has been described
previously (2). Polyclonal CTL derived from CBA mice and specific for the amino acid se-
quence 50-63 derived from the NP of A/NT/60/68 in association with H-2Kk were induced
in influenza-infected mice as described previously (5). Peptides were synthesized by solid
phasetechniques on asynthesizer (430A; AppliedBiosystems, Inc.) as described (2)andwere
kindly supplied by Jonathan Rothbard (Imperial Cancer Research Fund, London, UK).
CytotoxicAssay.
￿
A standard 6-h "Cr release assay was used as previously described using
either L cells transfected with the class I gene H-2D6 (18), or untransfected L cells. 2-5 x
106 target cells were infected with 10 plaque-forming units (PFU) per cell of recombinant
vaccinia and labeled with 5'Cr for 90 min. After being washed twice, the cells were resus-
pended at 106 cell/ml in RPMI/10% FCS for 4 h at 37oC, washed twice, and used in the
assay. In experiments with cycloheximide, target cells were resuspended in RPMI/10% FCS
containing 2 x 10-4 M cycloheximide for 30 min before infection with vaccinia virus. All
subsequent manipulation of the cells(including thewashes)were as above but included cyclo-
heximide at the same concentration. In experiments where peptides were included in the
assay, these were present throughout the period of contact between CTL and target cells as
described (2), at a final concentration of 2 x 10-5 M. Percent specific chromium release was
calculated as: 100 x (release by CTL - medium release)/(2.5% Triton release - medium
release). Allpoints were measured in duplicate against quadruplicate controls. Spontaneous
51Cr release in the absence of CTL ranged between 12 and 19% in all experiments.
Results
The CTLclone F5 recognizes the peptide 366-379 of NP in association with the
class I molecule Db (2). Fig. 1 a shows that F5 recognized L/Db cells (L cells trans-
fected with the gene coding for Db) infected with 366-379-NP-VAC 7.5K as
efficiently as L/Db cells infected with a recombinant vaccinia virus expressing a rap-
idly degraded form of the complete NP molecule (17) or influenza virus (data not
shown). Recognition of 366-379-NP-VAC 7.5K-infected cells by F5 was class I re-i J
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FIGURE 1.
￿
Recognition by the H-2 Db-restricted CTL clone F5 (a, b, d, and e), or polyclonal
H-2 K'-restricted CBACTL (c) of target cells treated in differentways: (a) F5 CTL and L/Db
targets, uninfected, O; infected with 366-379-NP-VAC 7.5K, 0; infected with Ub-RNP-VAC
7.5K(17), A; (b)F5 CTLand untransfected Ltargets, uninfected, O; infected with 366-379-NP-
VAC 7.5K, /; infected with Ub-RNP-VAC 7.5K, A; (c) polyclonal CBA CTL and untrans-
fected L targets, uninfected, O; infected with 366-379-NP-VAC 7.5K, /; infected with Ub-R
NPVAC 7.5K, A; (d) F5 CTL andL/Db targets, uninfected, O; uninfected and cycloheximide
treated, A; infected with 366-379-NP-VAC 7.5K, /; cycloheximide treated and infected with
366-379-NP-VAC 7.5K, "; (e)F5 CTL and L/Db targets, uninfected, O; uninfected andtreated
with cycloheximide, A; exposed to peptide 365-379 of NP, p; treated with cycloheximide and
exposed to peptide 365-379 of NP, +.
stricted, as F5 failed to recognize infected L cells that did not express Db (Fig. 1
b). Fig. 1 c demonstrates that recognition of 366-379-NP-VAC 7.5K-infected cells
was antigen specific, becausea polyclonal CTL line derived from CBA (H-2k) mice
specific forthe NP sequence 50-63 (5) did not lyse 366-379-NP-VAC 7.5K-infected
Lcells. The polyclonal CTLline didlyse Lcells infected with Ub-arg-NP-VAC 7.5K
that expressed the complete molecule containing the epitope defined with peptide
50-63 (Fig. 1 c).
To show that clone F5 recognized the peptide sythesized in infected target cells,
and not free peptide contaminating the recombinant vaccinia preparation, cyclo-
heximide wasused to inhibit protein synthesis in the 366-379-NP-VAC 7.5K-infected
L/Db cells. Fig. 1 dshows that presentation of the epitope 366-379 in recombinant
vaccinia-infected cells to clone F5 was completely inhibited by 2 x 10-4 M cyclo-
heximide. In contrast, Fig. 1 eshows that an identical treatment of target cells with
cycloheximide had no significant effect on presentation by L/Db ofexternally added
peptide. These results are consistent with newly synthesized peptide being recog-
nized by clone F5 at the surface of 366-379-NP-VAC 7.5K-infected target cells.
To show that recognition by clone F5 was not due to release of peptide from cells
damaged by vaccinia infection, we did amixing experiment. Equalnumbersof unin-
fected "Cr-labeled L/Db cells and unlabeled 366-379-NP-VAC 7.5K-infected L/Db
cells were mixedand incubatedwith clone F5. We could find no evidence fortransfer
of peptide between target cells (Fig. 2).1054
￿
GOULD ET AL.
￿
BRIEF DEFINITIVE REPORT
FIGURE 2 .
￿
Mixing experiment to test for transfer of peptide between
target cells . Clone F5 was incubated in U-bottomed wells at a ratio of
10:1 with L/Db target cells treated as follows : (1) "Cr-labeled, unin-
fected ; (2) "Cr-labeled, 366-379-NP-VAC 7.5K infected ; (3) "Cr-labeled
uninfected mixed with an equal number (104) of unlabeled cells infected
with 366-379-NP-VAC 7.5K ; (4) unlabeled, uninfected cells mixed with
an equal number of S'Cr-labeled 366-379-NP-VAC 7.5K-infected cells .
The "Cr release assay was done as described in Materials and Methods .
All points were measured in quadruplicate.
Discussion
We have previously shown that target cells synthesizing deletion mutants ofboth
influenza NP and HA that lacked hydrophobic signal sequences were recognized
efficiently by CTL, implying that signal-dependent transport across the membrane
of the rough endoplasmic reticulum did not play a role in presentation of epitopes
to class I-restricted CTL (1, 13) . This was particularly clear for HA, as deletion
of the N112-terminal signal sequence actually enhanced presentation of epitopes to
CTI, in recombinant vaccinia-infected target cells, while preventing transport of
the molecule into the endoplasmic reticulum, as determined by the lack of detect-
able glycosylation of nascent signal-deleted HA chains (17) .
We extend these results by showing that a minimal peptide epitope, synthesized
by recombinant vaccinia virus in infected cells, is presented to class I-restricted CTL.
Although there is no direct evidence that only a 15-amino acid peptide of NP is
synthesized in the infected cells, the expression construct contains two sequential
termination codons in frame with the epitope sequence . If alternative translational
initiation sites were used, either even shorter NP peptides or sequences unrelated
to NP would be made. Neither of these would be recognized by clone F5 (2).
Vaccinia virus carries out its entire life cycle in the cytoplasm of infected cells,
so that the NP peptide should be synthesized in the cytosol . This implies that the
NP epitope, consisting of residues 366-379, contains sufficient information to be
transported from the cytoplasm to the cell surface . It is conceivable that vaccinia-
encoded proteins mayhave some effect in assisting transport, although vaccinia in-
fection tends to inhibit rather than assist presentation ofepitopes to class I-restricted
CTL (19) .
An additional point of interest is that the inhibitory effect of vaccinia infection
on presentation of theNP epitope 366-379 in cells expressing the full-length mole-
cule (17) is overcome by expressing the epitope as a peptide. This is consistent with
the vaccinia inhibitory effect acting at a point before transport and association of
the epitope with class I molecules, and would be explained by specific inhibition
of proteolysis .
Our results are consistent with a previously proposed hypothesis that large pro-
tein antigens are degraded in the cytoplasm to short peptides, which at least in the
case of theepitope studied here, contain sufficient information to allow passageacross
the bilipid membrane (1, 2) . We can only speculate on the nature of the peptide
transportmechanism. It is likely to be constitutive as it must be active in uninfected
cells expressing transfected viralgenes (18, 20, 21) . It must also have abroad specificityGOULD ET AL.
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in order to transport peptides of widely differing sequence (1-12). It is noteworthy
that the sequence 366-379 of NP contains nine charged or polar residues and is
hydrophilic.
Summary
A recombinant vaccinia has been designed to express amino acids 366-379 of
influenza nucleoprotein, previously shown to be the minimal epitope recognized
by a class I-restricted cytotoxic T cell clone. Target cells infected with the recom-
binant vaccinia virus expressing this peptide are recognized by CTL as efficiently
as target cells expressing the complete nucleoprotein. The results imply the exis-
tence of a peptide transport system that constitutively passes the products of degraded
proteins from the cytoplasm into a membrane-bound compartment of the cell.
We thank Jonathan Rothbard for supplying peptides, Cetus Corp. (Emeryville, CA) for
supplying rIL-2, and Hilary Scotney for technical support.
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